Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

Highlights • Lipidated dengue-4 envelope protein domain III has the proper conformation to compete for cellular binding sites with dengue-4 virus. • Lipidated dengue-4 envelope protein domain III stimulates neutralizing antibody responses without exogenous adjuvants. • Viremia levels are reduced in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-03, Vol.32 (12), p.1346-1353
Hauptverfasser:	Chiang, Chen-Yi, Hsieh, Chun-Hsiang, Chen, Mei-Yu, Tsai, Jy-Ping, Liu, Hsueh-Hung, Liu, Shih-Jen, Chong, Pele, Leng, Chih-Hsiang, Chen, Hsin-Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals Antibodies, Neutralizing - blood Antibodies, Viral - blood Applied microbiology Biological and medical sciences Bone marrow Cell Line Cricetinae Dengue - prevention & control Dengue fever Dengue Vaccines - immunology Dengue virus Dengue virus type 4 Envelope protein domain III Female Fundamental and applied biological sciences. Psychology Immunity, Humoral Immunization Immunogenicity Lipids - immunology Lipoprotein Medical research Mice Mice, Inbred BALB C Microbiology Miscellaneous Neutralization Tests Protein Folding Protein Structure, Tertiary Recombinant Proteins - immunology Studies Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vector-borne diseases Viral Envelope Proteins - immunology Viremia - prevention & control Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Lipidated dengue-4 envelope protein domain III has the proper conformation to compete for cellular binding sites with dengue-4 virus. • Lipidated dengue-4 envelope protein domain III stimulates neutralizing antibody responses without exogenous adjuvants. • Viremia levels are reduced in mice immunized with lipidated dengue-4 envelope protein domain III.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.01.041